One‐year results of the first‐in‐man study investigating the atrial flow regulator for left atrial shunting in symptomatic heart failure patients: the PRELIEVE study
C Paitazoglou, MW Bergmann… - European journal of …, 2021 - Wiley Online Library
Aims Attenuating exercise‐induced elevated left atrial pressure with an atrial shunt device is
under clinical investigation for treatment of symptomatic heart failure (HF). Methods and …
under clinical investigation for treatment of symptomatic heart failure (HF). Methods and …
The AFR-PRELIEVE trial: a prospective, non-randomised, pilot study to assess the Atrial Flow Regulator (AFR) in heart failure patients with either preserved or …
C Paitazoglou, R Özdemir, R Pfister… - …, 2019 - avesis.kocaeli.edu.tr
The AFR-PRELIEVE trial: a prospective, non-randomised, pilot study to assess the Atrial Flow
Regulator (AFR) in heart failure pa Page 1 INTERVENTIONS FOR VALVULAR DISEASE AND …
Regulator (AFR) in heart failure pa Page 1 INTERVENTIONS FOR VALVULAR DISEASE AND …
Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial
Background Placement of an interatrial shunt device reduces pulmonary capillary wedge
pressure during exercise in patients with heart failure and preserved or mildly reduced …
pressure during exercise in patients with heart failure and preserved or mildly reduced …
Rationale and design of the reduce elevated left atrial pressure in patients with heart failure (reduce LAP-HF) trial
G Hasenfuss, F Gustafsson, D Kaye, SJ Shah… - Journal of Cardiac …, 2015 - Elsevier
Objective Heart failure with preserved ejection fraction (HFpEF) is characterized by elevated
left atrial pressure during rest and/or exercise. The Reduce LAP-HF (Reduce Elevated Left …
left atrial pressure during rest and/or exercise. The Reduce LAP-HF (Reduce Elevated Left …
Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in …
T Feldman, L Mauri, R Kahwash, S Litwin… - Circulation, 2018 - Am Heart Assoc
Background: In nonrandomized, open-label studies, a transcatheter interatrial shunt device
(IASD, Corvia Medical) was associated with lower pulmonary capillary wedge pressure …
(IASD, Corvia Medical) was associated with lower pulmonary capillary wedge pressure …
Transcatheter InterAtrial Shunt Device for the treatment of heart failure: Rationale and design of the pivotal randomized trial to REDUCE Elevated Left Atrial Pressure …
N Berry, L Mauri, T Feldman, J Komtebedde… - American heart …, 2020 - Elsevier
Background A randomized, sham-controlled trial in patients with heart failure (HF) and left
ventricular ejection fraction (LVEF)≥ 40% demonstrated reductions in pulmonary capillary …
ventricular ejection fraction (LVEF)≥ 40% demonstrated reductions in pulmonary capillary …
One-year safety and clinical outcomes of a transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction in the reduce elevated …
Importance In patients with heart failure (HF) and left ventricular ejection fraction (LVEF)
equal to or greater than 40%, a transcatheter interatrial shunt device (IASD; Corvia Medical) …
equal to or greater than 40%, a transcatheter interatrial shunt device (IASD; Corvia Medical) …
Latent pulmonary vascular disease may alter the response to therapeutic atrial shunt device in heart failure
BA Borlaug, J Blair, MW Bergmann, H Bugger… - Circulation, 2022 - Am Heart Assoc
Background: In REDUCE LAP-HF II (A Study to Evaluate the Corvia Medical, Inc IASD
System II to Reduce Elevated Left Atrial Pressure in Patients With Heart Failure) …
System II to Reduce Elevated Left Atrial Pressure in Patients With Heart Failure) …
A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicentre, open-label, single-arm, phase 1 trial
G Hasenfuß, C Hayward, D Burkhoff, FE Silvestry… - The Lancet, 2016 - thelancet.com
Background Heart failure with preserved ejection fraction (HFPEF) is a common, globally
recognised, form of heart failure for which no treatment has yet been shown to improve …
recognised, form of heart failure for which no treatment has yet been shown to improve …
One-year outcomes after transcatheter insertion of an interatrial shunt device for the management of heart failure with preserved ejection fraction
DM Kaye, G Hasenfuss, P Neuzil, MC Post… - Circulation: Heart …, 2016 - Am Heart Assoc
Background—Heart failure with preserved ejection fraction has a complex pathophysiology
and remains a therapeutic challenge. Elevated left atrial pressure, particularly during …
and remains a therapeutic challenge. Elevated left atrial pressure, particularly during …